FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387083025> ?p ?o ?g. }

• W4387083025 abstract "Abstract Background Mantle Cell Lymphoma (MCL) is an aggressive, rare form of non-Hodgkin B-cell lymphoma. Measurable Residual Disease (MRD) assessment can provide useful information when assessing and tracking response to therapy, refining treatment and predicting clinical outcome for subjects with B-cell lymphoproliferative diseases. One method of MRD detection is to identify and track specific clonal immunoglobulin heavy chain (IGH) gene rearrangement sequences on a next-generation sequencing (NGS) platform. Here, we present the NGS-based B-cell MRD Assay with 10−6 sensitivity for detecting MRD in malignancies in mantle cell lymphoma (MCL). Methods Residual DNA samples from different specimen types (44 BM and 77 PB) at different post-treatment time points were obtained from anonymized 47 MCL subjects that had been enrolled in a study approved by the Spanish Group of Lymphoma and Autologous Stem Cell Transplantation (clinical trial: NCT02682641, publication reference: 10.1200/JCO.21.02321). 121 of these follow up samples were tested by the B-cell MRD Assay by tracking the clonal sequences detected in corresponding baseline samples. Among them, 90 follow up samples were paired PB and BM samples. The B-cell MRD Assay workflow consists of DNA extraction and PCR based library preparation with proprietary multiplex master mixes (MMx) targeting either IGH Framework 1 (FR1) or 3 (FR3) regions, which both track the patient- and tumor-specific CDR3 sequence. Purified libraries are then equimolar pooled and sequenced on Illumina’s NextSeq Dx platform. The FASTQ output files from sequencing are analyzed using Invivoscribe’s B-Cell MRD Software-NextSeqDx. Results from Invivoscribe were compared to the results from Salamanca lab that were generated by qPCR. Results Based on the results from B-cell MRD Assay, 115/121 (95%) samples were valid, 42/115 (37%) valid samples had, “MRD Detected”, and 73/115 (63%) samples had, “MRD Not Detected”, with an “MRD Detection” rate of 28% in PB and 50% in BM specimen types. When comparing MRD detectable status between paired PB and BM samples from 36 MCL subjects, 30/44 (68%) paired samples had same MRD call and were concordant, whereas 14/44 (32%) calls were discordant. More specifically, 12/14 (86%) discordant samples had PB specimen type with a “MRD Not detected” call, whereas the paired BM specimen showed a “MRD Detected” call. Overall, in comparison with the MRD results (n = 84) provided by Salamanca lab using qPCR method, the B-cell MRD Assay demonstrated concordance of 80%, PPA of 79%, and NPA of 80% for MRD detection in MCL samples. Conclusion Good concordance was observed between the qPCR used at Salamanca and Invivoscribe’s B-cell MRD assay. It was important to note that the BM specimen type was determined to be more sensitive in detecting MRD when compared to PB in assessment of paired PB and BM samples. These results demonstrate that the B-cell MRD Assay can be utilized for MRD detection in follow-up sample types for MCL subjects." @default.
• W4387083025 created "2023-09-28" @default.
• W4387083025 creator A5001796193 @default.
• W4387083025 creator A5004068726 @default.
• W4387083025 creator A5018618823 @default.
• W4387083025 creator A5020823067 @default.
• W4387083025 creator A5025268748 @default.
• W4387083025 creator A5035567665 @default.
• W4387083025 creator A5042397189 @default.
• W4387083025 date "2023-09-27" @default.
• W4387083025 modified "2023-09-28" @default.
• W4387083025 title "B-355 Measurable Residual Disease Detection in Mantle Cell Lymphoma (MCL) Subjects Using NGS B-Cell MRD Assay" @default.
• W4387083025 doi "https://doi.org/10.1093/clinchem/hvad097.667" @default.
• W4387083025 hasPublicationYear "2023" @default.
• W4387083025 type Work @default.
• W4387083025 citedByCount "0" @default.
• W4387083025 crossrefType "journal-article" @default.
• W4387083025 hasAuthorship W4387083025A5001796193 @default.
• W4387083025 hasAuthorship W4387083025A5004068726 @default.
• W4387083025 hasAuthorship W4387083025A5018618823 @default.
• W4387083025 hasAuthorship W4387083025A5020823067 @default.
• W4387083025 hasAuthorship W4387083025A5025268748 @default.
• W4387083025 hasAuthorship W4387083025A5035567665 @default.
• W4387083025 hasAuthorship W4387083025A5042397189 @default.
• W4387083025 hasBestOaLocation W43870830251 @default.
• W4387083025 hasConcept C104317684 @default.
• W4387083025 hasConcept C126322002 @default.
• W4387083025 hasConcept C143998085 @default.
• W4387083025 hasConcept C153911025 @default.
• W4387083025 hasConcept C159654299 @default.
• W4387083025 hasConcept C203014093 @default.
• W4387083025 hasConcept C2777525834 @default.
• W4387083025 hasConcept C2778453870 @default.
• W4387083025 hasConcept C2778559949 @default.
• W4387083025 hasConcept C2779338263 @default.
• W4387083025 hasConcept C2779823535 @default.
• W4387083025 hasConcept C2780007613 @default.
• W4387083025 hasConcept C2781188995 @default.
• W4387083025 hasConcept C2911091166 @default.
• W4387083025 hasConcept C49105822 @default.
• W4387083025 hasConcept C502942594 @default.
• W4387083025 hasConcept C54355233 @default.
• W4387083025 hasConcept C60644358 @default.
• W4387083025 hasConcept C71924100 @default.
• W4387083025 hasConcept C78063203 @default.
• W4387083025 hasConcept C86803240 @default.
• W4387083025 hasConceptScore W4387083025C104317684 @default.
• W4387083025 hasConceptScore W4387083025C126322002 @default.
• W4387083025 hasConceptScore W4387083025C143998085 @default.
• W4387083025 hasConceptScore W4387083025C153911025 @default.
• W4387083025 hasConceptScore W4387083025C159654299 @default.
• W4387083025 hasConceptScore W4387083025C203014093 @default.
• W4387083025 hasConceptScore W4387083025C2777525834 @default.
• W4387083025 hasConceptScore W4387083025C2778453870 @default.
• W4387083025 hasConceptScore W4387083025C2778559949 @default.
• W4387083025 hasConceptScore W4387083025C2779338263 @default.
• W4387083025 hasConceptScore W4387083025C2779823535 @default.
• W4387083025 hasConceptScore W4387083025C2780007613 @default.
• W4387083025 hasConceptScore W4387083025C2781188995 @default.
• W4387083025 hasConceptScore W4387083025C2911091166 @default.
• W4387083025 hasConceptScore W4387083025C49105822 @default.
• W4387083025 hasConceptScore W4387083025C502942594 @default.
• W4387083025 hasConceptScore W4387083025C54355233 @default.
• W4387083025 hasConceptScore W4387083025C60644358 @default.
• W4387083025 hasConceptScore W4387083025C71924100 @default.
• W4387083025 hasConceptScore W4387083025C78063203 @default.
• W4387083025 hasConceptScore W4387083025C86803240 @default.
• W4387083025 hasIssue "Supplement_1" @default.
• W4387083025 hasLocation W43870830251 @default.
• W4387083025 hasOpenAccess W4387083025 @default.
• W4387083025 hasPrimaryLocation W43870830251 @default.
• W4387083025 hasRelatedWork W1501529729 @default.
• W4387083025 hasRelatedWork W2077075388 @default.
• W4387083025 hasRelatedWork W2093466869 @default.
• W4387083025 hasRelatedWork W2398965438 @default.
• W4387083025 hasRelatedWork W2891996278 @default.
• W4387083025 hasRelatedWork W3008207576 @default.
• W4387083025 hasRelatedWork W3008632999 @default.
• W4387083025 hasRelatedWork W3098902611 @default.
• W4387083025 hasRelatedWork W3155878410 @default.
• W4387083025 hasRelatedWork W4378640046 @default.
• W4387083025 hasVolume "69" @default.
• W4387083025 isParatext "false" @default.
• W4387083025 isRetracted "false" @default.
• W4387083025 workType "article" @default.